KROMATID®

• 21/08/2025
• Series C
• $8,000,000

Revolutionizing gene editing analysis for precision medicine and cutting-edge research.

For cell and gene therapy researchers, biotech and pharma companies, and regulatory professionals, KROMATID’s KROMASURE Platform is the genomic characterization solution that provides high-confidence, single-cell insights into chromosomal integrity, structural variants, and transgene mapping.
Unlike traditional sequencing methods, our technology directly visualizes up to thousands of single cells at a time, offering scalable, actionable data with unprecedented clarity, helping you confidently advance research and meet FDA regulatory requirements.

Visit our website to learn how we can support your research.

---

---